Portfolio
We seek investments in innovative companies that are developing first-in-class products for growth markets. Investments have been made in various therapeutic areas, including oncology, inflammation, cardiovascular, metabolic and CNS.
Fibrex Medical - Austria | |||
| Fund engagement: | 2006 | Activity: | Drug development Reperfusion injury |
| Status: | Exited - Licensing | Contact: | www.fibrexmedical.com |
Elara Phamraceuticals - Germany | |||
| Fund engagement: | 2006 | Activity: | Drug development HIF pathway |
| Status: | Pre-clinical development | Contact: | www.elarapharma.com |
Lipid Therapeutics - Germany | |||
| Fund engagement: | 2008 | Activity: | Drug development Colitis ulcerosa |
| Status: | Partnered - Phase IIB | Contact: | www.lipid-therapeutics.com |
Affectis Pharmaceuticals - Germany | |||
| Fund engagement: | 2005 | Activity: | Drug development Depression |
| Status: | Partnered - Preclinical | Contact: | www.affectis.com |
Immatics - Germany | |||
| Fund engagement: | 2004 | Activity: | Drug development Cancer vaccines |
| Status: | Clinical phase II/III | Contact: | www.immatics.com |
Endoart - Switzerland | |||
| Fund engagement: | 2006 | Activity: | Medtech Obesity |
| Status: | Exited - Aquisition | Contact: | n.a. |
Vasopharm - Germany | |||
| Fund engagement: | 2006 | Activity: | Drug development Traumatic brain injury |
| Status: | Clinical phase IIA | Contact: | www.vasopharm.com |
Hybricore - Germany | |||
| Fund engagement: | 2003 | Activity: | Services Antibody production |
| Status: | Exited - Licensing | Contact: | n.a. |
Combinature - Germany | |||
| Fund engagement: | 2006 | Activity: | Drug development Anti-infectives |
| Status: | Exited - Secondary transaction | Contact: | n.a. |
Jado Technologies - Germany | |||
| Fund engagement: | 2006 | Activity: | Drug development Allergy |
| Status: | Preclinical | Contact: | www.jado-tech.com |
Cenix Bioscience - Germany | |||
| Fund engagement: | 2002 | Activity: | Services RNAi based target discovery |
| Status: | Profitable | Contact: | www.cenix.com |
ArthroKinetics - Germany | |||
| Fund engagement: | 2003 | Activity: | Medtech Cartilage replacement |
| Status: | Exited - IPO | Contact: | www.arthro-kinetics.com |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
"Since their first investment, EMBL Ventures has played a constructive and positive role within Affectis. Providing their extensive network, supporting the company through the board of directors or bringing in new projects, we have developed a fruitful relationship."
Prof. Herbert Stadler; CEO, Affectis Pharmaceuticals, Munich (2002-2010)